Cardiomyopathy Market
Global Cardiomyopathy Market Size, Share & Trends Analysis Report by Type (Dilated Cardiomyopathy, Restrictive Cardiomyopathy, Unclassified Cardiomyopathy, Hypertrophic Cardiomyopathy, and Arrhythmogenic Right Ventricular Dysplasia), by Diagnosis Test (Blood Tests, Cardiac MRI, Chest X-Ray, Cardiac CT Scan, Echocardiogram, Treadmill Stress Test, Electrocardiogram (ECG), Cardiac Catheterization, Genetic Testing or Screening) by Treatment (Medication, Surgically Implanted Devices, Nonsurgical Procedures, Surgery) and by End-User (Homecare, Hospitals and Clinics, Diagnostic Center, and Other) Forecast Period (2022-2028)
The global cardiomyopathy market is anticipated to grow at a significant CAGR of 4.2% during the forecast period. Cardiomyopathy is a disease of the heart muscle. It affects any age group and is a serious lifelong condition. The major factors that contribute to the growth of the market are advancement in understanding and managing cardiomyopathy and a rise in incidences of congestive heart failure, coronary heart disease, and heart attack. However, the high cost of diagnosis & treatment and lack of public awareness is considered to be the major restraining factors in the growth of the market. Increasing medical tourism in emerging countries and increasing research and development for cardiomyopathy treatment are developing numerous opportunities for the growth of the cardiomyopathy market.
Moreover, major types of cardiomyopathy include dilated cardiomyopathy, hypertrophic cardiomyopathy, and restrictive cardiomyopathy. These types of cardiomyopathy can be inherited. Further, it can be caused by a viral infection in the heart or heart attack. Dilated cardiomyopathy occurs when the muscles of the heart begin to stretch and become thinner. Hypertrophic cardiomyopathy happens when the muscles of heart cells enlarge and cause the walls of the heart to thicken. Restrictive cardiomyopathy tends to affect older adults. The heart becomes rigid as the abnormal tissue replaces the normal heart muscle so the heart muscle is unable to relax.
Impact of COVID-19 Pandemic on Global Cardiomyopathy Market
Due to high viral transmissibility, there is a considerably higher risk for frontline healthcare workers to develop severe acute respiratory syndrome COVID-19. Various diagnostic imaging procedures particularly chest x-ray, and cardiac CTct scans were at high risk due to surface transmission as a result of frequent direct contact with large numbers of patients. Moreover, it has also created some new challenges for surgeons, hospitals, and patients in many hospitals at that time reduced non-emergency surgeries, and also minimally invasive diagnostic procedures, and patients were delaying their not necessary surgeries due to the fear of getting affected by COVID-19.
Segmental Outlook
The global cardiomyopathy market is segmented on the basis of type, diagnosis test, treatment, and end user. On the basis of type, the market is sub-divided into dilated cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular dysplasia. Based on the diagnosis type the market is bifurcated into blood tests, cardiac MRI, chest x-ray, cardiac Ct Scan, echocardiogram, treadmill stress test, electrocardiogram (ECG), cardiac catheterization, genetic testing or screening. By treatment, the market is sub-categorized into medication, surgically implanted devices, nonsurgical procedures, and surgery. By end-user, the market is sub-classified into homecare, hospitals and clinics, diagnostic centers, and others. Among the treatment segment, surgically implanted devices are attributed to fastest growing owing to as this device helps in maintaining proper heart rhythm and sends a small shock to the heart muscle if the rhythm becomes abnormal. Moreover, as these devices send a fast impulse to the heart muscle to get it back into a normal rhythm and it also reduces sudden cardiac arrest attributed to their features patients are awarded and adopting that in contributing to the market growth.
Global Cardiomyopathy Market Share by Type, 2021 (%)
The Dilated Cardiomyopathy Segment is Dominating the Global Cardiomyopathy Market
Dilated cardiomyopathy is holding a prominent share among all the segments in the market owing to the rising life expectancy and growing prevalence of several heart problems such as heart strokes, and blockage among others. Moreover, with increased awareness about healthy living and concerns about health coupled with it the demand for cardiomyopathy treatments and diagnosis is been increased. Furthermore, the rising number of people suffering from cardiac muscle infections, are factors that help in driving the market growth. For instance, in February 2022, Renovacor partnered with Dilated Cardiomyopathy (DCM) Foundation, the American Association of Heart Failure Nurses (AAHFN), and the Heart Failure Society of America (HFSA). This partnership is to raise awareness of cardiomyopathies and to educate the patient and provider communities about the cardiomyopathy and risk related to it.
Regional Outlooks
The global cardiomyopathy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East &Africa, and Latin America. North America is estimated to account for a major share of the global cardiomyopathy market owing to the increasing incidence of heart diseases such as coronary heart disease or heart attack in this region.
Global Cardiomyopathy Market Growth, by Region 2022-2028
The Asia-Pacific Region is Fastest Growing in the Global Cardiomyopathy Market
The Asia-Pacific is estimated to be the fastest growing region due to increasing healthcare expenditure, a growing geriatric population, and the presence of a larger patient pool. Further, increasing demand from the Asia Pacific region attracts the market players to expand their geographical presence in the region. Moreover, owing to increasing medical tourism in emerging countries such as India and China in Asia Pacific region is estimated to be the fastest growing region in the cardiomyopathy market.
Market Players Outlook
The competitive landscape includes key strategies of leading players, recent developments, and key company analysis. The major players that contribute to the growth of the market include- Becton and Dickson & Co., Boston Scientific Corp., Mylan N.V, Pfizer, Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd., and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new Deployment launches, to stay competitive in the market. For instance, in October 2020, Bristol Myers Squibb acquired MyoKardia Inc., for $13.1 billion, to explore the full potential of mavacamten in additional indications, including non-obstructive HCM. The acquisition was for a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy. the new drug is to be submitted to the U.S. Food and Drug Administration (FDA).
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cardiomyopathy market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current TYPE Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Cardiomyopathy Market
• Recovery Scenario of Global Cardiomyopathy Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Cardiomyopathy Market by Type
4.1.1. Dilated Cardiomyopathy
4.1.2. Restrictive Cardiomyopathy
4.1.3. Unclassified Cardiomyopathy
4.1.4. Hypertrophic Cardiomyopathy
4.1.5. Arrhythmogenic Right Ventricular Dysplasia
4.2. Global Cardiomyopathy Market by Diagnosis Test
4.2.1. Blood Tests
4.2.2. Cardiac MRI
4.2.3. Chest X-Ray
4.2.4. Cardiac CT Scan
4.2.5. Echocardiogram
4.2.6. Treadmill Stress Test
4.2.7. Electrocardiogram (Ecg)
4.2.8. Cardiac Catheterization
4.2.9. Genetic Testing Or Screening
4.3. Global Cardiomyopathy Market by Treatment
4.3.1. Medication
4.3.2. Nonsurgical Procedures
4.3.2.1. Septal Ablation
4.3.2.2. Radiofrequency Ablation
4.3.3. Surgery
4.3.3.1. Septal Myectomy
4.3.3.2. Heart Transplant
4.4. Global Cardiomyopathy Market by End-User
4.4.1. Homecare
4.4.2. Hospitals And Clinics
4.4.3. Diagnostic Center
4.4.4. Other
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott
6.2. AstraZeneca
6.3. Becton, Dickinson and Co.
6.4. BIOMÉRIEUX, INC.
6.5. Bio-Rad Laboratories, Inc
6.6. Boston Scientific Corp.
6.7. Bristol-Myers Squibb Co.
6.8. F. Hoffmann-La Roche Ltd
6.9. Ionis Pharmaceuticals
6.10. Janssen Pharmaceuticals, Inc.
6.11. Laboratory Corp.
6.12. Medtronic Plc.
6.13. Merck & Co., Inc.
6.14. Mylan N.V.
6.15. Novartis International AG
6.16. PerkinElmer
6.17. Pfizer Inc.
6.18. Randox Laboratories
6.19. Response Biomedical Corp.
6.20. Sanofi S.A
6.21. Siemens Healthcare GmbH
6.22. Takeda Pharmaceutical Co. Ltd.
6.23. Teva Pharmaceutical Industries Ltd.
6.24. Thermo Fisher Scientific Inc.
6.25. Vericel Corp.
1. GLOBAL CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL DILATED CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL RESTRICTIVE CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL UNCLASSIFIED CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL HYPERTROPHIC CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TEST, 2021-2028 ($ MILLION)
8. GLOBAL BLOOD TESTS IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL CARDIAC MRI IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL CHEST X-RAY IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL CARDIAC CT SCAN IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL ECHOCARDIOGRAM IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL TREADMILL STRESS TEST IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL ELECTROCARDIOGRAM (ECG) IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL CARDIAC CATHETERIZATION IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL GENETIC TESTING OR SCREENING IN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. GLOBAL CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENTS, 2021-2028 ($ MILLION)
18. GLOBAL CARDIOMYOPATHY BY MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
19. GLOBAL CARDIOMYOPATHY BY NONSURGICAL PROCEDURES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
20. GLOBAL CARDIOMYOPATHY NONSURGICAL PROCEDURES MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. GLOBAL CARDIOMYOPATHY BY SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
22. GLOBAL CARDIOMYOPATHY SURGERY MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. GLOBAL CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
24. GLOBAL CARDIOMYOPATHY IN HOMECARE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
25. GLOBAL CARDIOMYOPATHY IN HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
26. GLOBAL CARDIOMYOPATHY IN DIAGNOSTIC CENTER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
27. GLOBAL CARDIOMYOPATHY IN OTHER END-USER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
28. NORTH AMERICAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. NORTH AMERICAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
30. NORTH AMERICAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TEST, 2021-2028 ($ MILLION)
31. NORTH AMERICAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENTS, 2021-2028 ($ MILLION)
32. NORTH AMERICAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
33. EUROPEAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
34. EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
35. EUROPEAN PHYSICAL VAPOR DEPOSITION (PVD)MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TEST, 2021-2028 ($ MILLION)
36. EUROPEAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENTS, 2021-2028 ($ MILLION)
37. EUROPEAN CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
38. ASIA-PACIFIC CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
39. ASIA-PACIFIC CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
40. ASIA-PACIFIC CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TEST, 2021-2028 ($ MILLION)
41. ASIA-PACIFIC CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENTS, 2021-2028 ($ MILLION)
42. ASIA-PACIFIC CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
43. REST OF THE WORLD CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
44. REST OF THE WORLD CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
45. REST OF THE WORLD CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS TEST, 2021-2028 ($ MILLION)
46. REST OF THE WORLD CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY TREATMENTS, 2021-2028 ($ MILLION)
47. REST OF THE WORLD CARDIOMYOPATHY MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL CARDIOMYOPATHY MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL CARDIOMYOPATHY MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL CARDIOMYOPATHY MARKET, 2021-2028 (%)
4. GLOBAL CARDIOMYOPATHY MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL DILATED CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL RESTRICTIVE CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL UNCLASSIFIED CARDIOMYOPATHY MARKET SHARE BY TREATMENTS, 2021 VS 2028 (%)
8. GLOBAL HYPERTROPHIC CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL CARDIOMYOPATHY MARKET SHARE BY DIAGNOSIS TEST, 2021 VS 2028 (%)
11. GLOBAL BLOOD TESTS IN CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL CARDIAC MRI IN CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL CHEST X-RAY IN CARDIOMYOPATHY MARKET SHARE BY TREATMENTS, 2021 VS 2028 (%)
14. GLOBAL CARDIAC CT SCAN IN CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL ECHOCARDIOGRAM IN CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL TREADMILL STRESS TEST IN CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL ELECTROCARDIOGRAM (ECG) IN CARDIOMYOPATHY MARKET SHARE BY TREATMENTS, 2021 VS 2028 (%)
18. GLOBAL CARDIAC CATHETERIZATION IN CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. GLOBAL GENETIC TESTING OR SCREENING IN CARDIOMYOPATHY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20. GLOBAL CARDIOMYOPATHY MARKET SHARE BY TREATMENTS, 2021 VS 2028 (%)
21. GLOBAL CARDIOMYOPATHY MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
22. GLOBAL CARDIOMYOPATHY SURGICALLY IMPLANTED DEVICES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
23. GLOBAL CARDIOMYOPATHY BY SURGICALLY IMPLANTED DEVICES MARKET SHARE BY TYPE, 2021 VS 2028 (%)
24. GLOBAL CARDIOMYOPATHY BY NONSURGICAL PROCEDURES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
25. GLOBAL CARDIOMYOPATHY BY NONSURGICAL PROCEDURES MARKET SHARE BY TYPE, 2021 VS 2028 (%)
26. GLOBAL CARDIOMYOPATHY BY SURGERY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
27. GLOBAL CARDIOMYOPATHY BY SURGERY MARKET SHARE BY TYPE, 2021 VS 2028 (%)
28. GLOBAL CARDIOMYOPATHY MARKET SHARE BY END-USER, 2021 VS 2028 (%)
29. GLOBAL CARDIOMYOPATHY FOR HOMECARE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
30. GLOBAL CARDIOMYOPATHY IN HOSPITALS AND CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
31. GLOBAL CARDIOMYOPATHY IN DIAGNOSTIC CENTER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%
32. GLOBAL CARDIOMYOPATHY IN OTHER END-USER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
33. US CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
34. CANADA CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
35. UK CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
36. FRANCE CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
37. GERMANY CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
38. ITALY CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
39. SPAIN CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
40. REST OF EUROPE CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
41. INDIA CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
42. CHINA CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
43. JAPAN CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
44. SOUTH KOREA CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
45. REST OF ASIA-PACIFIC CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
46. REST OF THE WORLD CARDIOMYOPATHY MARKET SIZE, 2021-2028 ($ MILLION)
